Kipps' group, who first reported that expression of transgenic murine CD40L on autologous B-CLL cells could induce an anti-tumor response after intravenous infusion [21], have subsequently shown that vaccinated patients develop an antibody response towards ROR1, a tyrosine kinase receptor involved in recognition of Wnt5a and involved in cell motility and asymmetric cell division, characteristics associated with stem cell behavior [22,23]. This evidence concerns the gene NTRK1 and B-cell chronic lymphocytic leukemia.